Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review

Journal of Surgical Oncology

Volumn 110, Issue 6, 2014, Pages 770-775

  Byers, Brett A ^a   Temple Oberle, Claire F ^a   Hurdle, Valerie ^a   McKinnon, J Greg ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

In transit melanoma; Interleukin 2; Intra lesional; Melanoma

Indexed keywords

INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BRONCHOSPASM; CANCER THERAPY; CHILL; CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; HAIR LOSS; HEADACHE; HUMAN; IN TRANSIT MELANOMA; INJECTION SITE SWELLING; LYMPHANGITIS; MALAISE; MELANOMA; MUSCLE CRAMP; NIGHT SWEAT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; QUALITY CONTROL; RASH; RIGOR; SWELLING; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT RESPONSE; URTICARIA; VITILIGO; XEROSTOMIA; INTRALESIONAL DRUG ADMINISTRATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS;

EID: 84919588074     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23702     Document Type: Article

References (40)

1. Pawlik TM, Ross MI, Johnson MM, et al.: Predictors and natural history of in-transit melanoma melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005;12:587-596.
2. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;36:6199-6206.
3. Huffman TA, Sterin WK: Ten-year survival with multiple metastatic malignant melanoma. Primary site unknown. Arch Surg 1973;106: 234-235.
4. Strauss A, Dritschilo A, Nathanson L, et al.: Radiation therapy of malignant melanomas: An evaluation of clinically used fraction-ation schemes. Cancer 1981;47:1262-1266.
5. Atallah E, Flaherty L: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193.
6. Algazi AP, Soon CW, Daud AI: Treatment of cutaneous melanoma: Current approaches and future prospects. Cancer Manage Res 2010; 2:197-211.
7. Tarhini AA, Agarwala SS: Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs 2005;6:1234-1239.
8. Eklund JW, Kuzel TM: A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004;16: 542-546.
9. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, et al.: Experience in the treatment of cutaneous in transit melanoma metastases and satellitoses with intralesional interleukin-2. Actas Dermosifiliogr 2009;100:571-585.
10. Wells GA, Shea B, O'Connell D, et al.: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiol-ogy/oxford.asp [Accessed June 2, 2012].
11. Dummer R, Rochlitz C, Velu T, et al.: Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. J Am Soc Gene Ther 2008;16:985-994.
12. Stewart AK, Lassam NJ, Quirt IC, et al.: Adenovector-mediated gene delivery of interleukin-2 in metastic breast cancer and melanoma: Results of a phase 1 clinical trial. Cancer Gene Ther 2002;6:350-363.
13. Garcia MS, Ono Y, Martinez SR, et al.: Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin-2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011;21:235-243.
14. Gutwald J, Groth W, Mahrle G: Peritumoral administered IL-2 induced tumor regression in melanoma. Pilot study. Hautarzt 1994;45:536-540.
15. Pfohler C, Steinhauser S, Wagner A, et al.: Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in two patients with malignant melanoma. Hautarzt 2004;55:171-175.
16. Loquai C, Nashan D, Metze D, et al.: Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases. Hautarzt 2004;55:176-181.
17. Schreiber S, kampgen E, Wagner E, et al.: Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase 1 study. Hum Gene Ther 1999;10:983-993.
18. Su PJ, Chen JS, Liaw CC, et al.: Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low dose interleukin-2 for patients with metastatic malignant melanoma. Chang Gung Med J 2011;51:478-486.
19. Palmer K, Moore J, Everard M, et al.: Gene therapy with autologous, interleukin-2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999;10:1261-1268.
20. Labarriere N, Pandolfino MC, Gervois N, et al.: Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002;51:532-538.
21. Rochlitz C, Dreno B, Jantscheff P, et al.: Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. Cancer Gene Ther 2002;9:289-295.
22. Adler A, Stein JA, Kedar E, et al.: Intralesional injection of interleukin-2 expanded autologous lymphocytes in melanoma and breast cancer patients: A pilot study. J Biol Response Mod 1984; 3:491-500.
23. Weide B, Eigentler TK, Plugfelder A, et al.: Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 2011;60:487-493.
24. Ridolfi L, Ridolfi R: Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogas-troenterology 2002;49:335-339.
25. Green DS, Dalgleish AG, Belonwu N, et al.: Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008;159:606-614.
26. Boyd KU, Wehrli BM, Temple-Oberle CF: Intra-lesional interleu-kin-2 for the treatment of in-transit melanoma. J Surg Oncol 2011; 104:711-717.
27. Weide B, Derhovanessian E, Pflugfelder A, et al.: High response rate after intratumoral treatment with interleukin-2: Results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010;116:4139-4146.
28. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al.: Intralesional granulocyte-monocyte colony stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001;15:218-223.
29. Green DS, Bodman-Smith MD, Dalgleish AG, et al.: Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156:337-345.
30. Radny P, Caroli UM, Bauer J, et al.: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-1626.
31. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 1981;47:207-214.
32. Park JO, Lee SI, Song SY, et al.: Measuring response in solid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33:533-537.
33. Phan GQ, Attia P, Steinberg SM, et al.: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-3482.
34. Sompayrac L: How the immune system works. 3rd edition. Malden, Massachusetts: Blackwell Publishing, 2008. pp. 21-22, 128-129.
35. Morgan DA, Ruscett FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193: 1007-1008.
36. Waldman TA: The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
37. Munoz CM, Sanchez JL, Martin-Garcia RF: Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004;30:1543-1545.
38. Wolf IH, Smolle J, Binder B, et al.: Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-276.
39. Bediakian AY, Millward M, Pehamberger H, et al.: Bcl-2 antisense (Oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen melanoma study group. J Clin Oncol 2006;24:4738-4745.
40. Kaufmann R, Spieth K, Leiter U, et al.: Tem-ozolomide in combination with interferon-alfa versus temozolo-mide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the dermatologic cooperative oncology group. J Clin Oncol 2005;23:9001-9007.